Polatuzumab
roche
['lymsm', 'nhl']
congress #asco22 | ryan c. lynch, md of presents results from a clinical trial of pola-da-epch-r in patients with aggressive b-cell #nhl (n=18) the trial met it's primary safety endpoint with only 3 dose-limiting-toxicities observed. #lymsm #cancerawareness #medicalcongress 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm